

Immuron Limited
 (ASX: IMC)

RESULTS OF ANNUAL GENERAL MEETING

Friday 29th November 2013

The Company wishes to advise that all resolutions were carried on show of hands.

In accordance with Listing Rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001, the following information is provided in relation to the resolutions considered by Members of the Company at the Annual General Meeting held today.

| Resolution | For | Against | Abstain | Proxy's Discretion* | Total Valid Proxies Received |
|--|-------------|------------|-------------|---------------------|------------------------------|
| 1 Adoption of Remuneration Report | 238,174,139 | 2,945,786 | 64,492,498 | 169,534,561 | 475,146,984 |
| 2 Election of Daniel Pollock as a Director | 189,334,855 | 694,481 | 65,583,087 | 219,534,561 | 475,146,984 |
| 3 Election of Stephen Anastasiou as a Director | 195,752,848 | 695,481 | 109,164,094 | 169,534,561 | 475,146,984 |
| 4 Approve the issue of 8,750,000 Shares to Grandlodge Pty Ltd | 195,467,295 | 60,145,128 | 168,326,929 | 51,207,632 | 475,146,984 |
| 5 Approve the issue of 2,604,167 Shares and 20,000,000 Options to Roger Aston | 195,467,295 | 981,034 | 59,164,094 | 219,534,561 | 475,146,984 |
| 6 Approve the issue of 1,875,000 Shares and 10,000,000 Options to Daniel Pollock | 189,048,302 | 60,145,128 | 6,418,993 | 219,534,561 | 475,146,984 |
| 7 Approve the issue of 10,000,000 Options to Stephen Anastasiou | 195,467,295 | 60,145,128 | 50,000,000 | 169,534,561 | 475,146,984 |
| 8 Approve the issue of 5,000,000 Shares and 10,000,000 Options to The CFO Solution | 252,131,389 | 981,034 | 2,500,000 | 219,534,561 | 475,146,984 |
| 9 Appointment of William Buck Audit (VIC) Pty Ltd as the Company's auditor | 255,279,892 | 238,245 | 94,286 | 219,534,561 | 475,146,984 |
| 10 Approval of additional capacity to issue Shares under ASX Listing Rule 7.1A | 188,932,387 | 66,680,036 | - | 219,534,561 | 475,146,984 |

* The Chairman voted undirected proxies in his control in favour of all resolutions.

On behalf of the Board



Phillip Hains
 Company Secretary

About Immuron Limited

Immuron is a biopharmaceutical company focused on oral immunotherapy treatments using dairy-derived antibody products for humans. Immuron is uniquely positioned with a versatile technology platform capable of generating a wide range of products with a high safety profile. This high safety profile makes it possible to complete pre-clinical studies relatively quickly and increases the prospect that the clinical development of Immuron's products will be expedited. Immuron's current products and product candidates target infectious diseases of the gastrointestinal tract, chronic diseases such as fatty liver/NASH, and influenza. Immuron has a product in the market, Travelan, for preventing travellers' diarrhoea.